Civilization Ventures

Important post by Dr. Pamela Klein for #BreastCancerAwarenessMonth. Please read. Pam is a preeminent leader and senior executive in #oncology, good friend, and we’re proud to say an advisor and supporter of our work at Civilization Ventures. We all know someone affected by #cancer - an early diagnosis is one of our best tools in the fight against this “emperor of all maladies”.

We are thrilled to announce our support for the incredible journey of Integrated Biosciences, Inc., as they raise $17.2M in seed funding to fuel their cutting-edge work in age-related diseases. 🧬 Using a powerful combination of synthetic biology and AI-driven small-molecule discovery, Integrated Biosciences is reimagining what’s possible in drug development. We’re excited to continue this journey alongside them as they accelerate their pipeline and bring life-changing therapies to the world. The future of medicine is just getting started! #SyntheticBiology #AI https://lnkd.in/eKccXvJ4

I am pleased to announce that #ForesightDx has successfully closed $33 million in new capital from our existing investors, including Foresite Capital, Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and University of Colorado's Healthcare Innovation Fund. This additional funding will be instrumental in advancing Foresight CLARITY™, our ultra-sensitive liquid biopsy MRD testing platform as we work towards delivering innovative diagnostics to patients.  Thank you to all our investors for their unwavering confidence and support of our company and mission!  #ctDNA #MRD #Oncology #PrecisionMedicine #Startup #ForesightCLARITY 

Today, we are thrilled to announce the successful closing of an oversubscribed Series B financing of $144M. This funding will propel the advancement of multiple programmed T cell product candidates to early clinical proof-of-concept in #ovariancancer and other #solidtumors, and further expand our pipeline and platform. We are also excited to welcome Jake Simson, PhD from RA Capital Management to our Board of Directors. Our lead program, OPB-101, is a mesothelin-specific CAR T cell enhanced by Outpace's proprietary technologies: OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™. OPB-101 has shown complete elimination of solid tumors in stringent in vivo models at very low treatment doses (as low as 50,000 cells) and is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. We extend our gratitude to our world-class syndicate of investors for believing in and supporting our mission to revolutionize treatment outcomes for #patients battling #solidtumors. Read more in our press release: https://lnkd.in/eimM3UZi The Series B financing brings our total capital raised to approximately $200 million and was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments (Alexandria Real Estate Equities, Inc.), and other undisclosed investors. Outpace’s existing investors ARTIS Ventures, Playground Global, Bristol Myers Squibb Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation, Sahsen Ventures, LLC, also participated in the round. #proteindesign #celltherapy #oncology #solidtumors #AI #biotech #syntheticbiology #seattle #CAR #TCR 

We're humbled to announce the acquisition of Civilization Ventures portfolio company Fluent BioSciences Inc. by Illumina - our 10th exit in the fund! Our thanks to the founders, executives and visionaries behind Fluent, including our co-investors at Samsara (Mike Dybbs) and Illumina VC (Wouter Meuleman): Sepehr Kiani, Kristina Fontanez, William (Bill) Hyun, Adam Abate, Brian McKernan, Gary Zweiger and many others. On a personal note, this marks my 3rd exit to Illumina as an investor/executive, and I'm humbled that our fund is able to play a role in building cutting-edge life sciences tools that are driving the future of biological innovation. https://lnkd.in/eHAYsRmE

We are thrilled to announce the acquisition of our portfolio company, Fluent BioSciences Inc., by Illumina, marking the 10th exit for our fund. Congratulations to the founders, executives and visionaries behind Fluent, including Sepehr Kiani and Brian McKernan.

🇺🇸 Happy early 4th of July from our team at CV 🇺🇸 If you are interested in learning more about the transformative potential of Generative AI in healthcare and life sciences, hear our founding GP Shahram Seyedin-Noor share his views as part of the Talk Gen AI panel at Swissnex below. #generativeai https://lnkd.in/gCmUzFgM

🔈 CV Fireside Chat Series: Sourcing Innovation We want to extend a heartfelt thank you to our speakers for the second installment of the "Sourcing Innovation" series, which focused on the journey of two CEOs who have successfully spun out their PhD projects. Shakked Halperin, PhD: CEO and Founder of Replace Therapeutics (Exited) and Rewrite Therapeutics (Exited), spun out of University of California, Berkeley Marco Lobba, Ph.D.: CEO and Co-Founder of CatenaBio, spun out of University of California, Berkeley In the Sourcing Innovation series, we aim to broaden the discussion around academic entrepreneurship by exploring the spin-out process from two crucial perspectives: the PIs who lay the groundwork and the PhD trainees-turned-CEOs who bring these innovations to market.

🔈 CV Fireside Chat Series: Sourcing Innovation We want to extend a heartfelt thank you to our speakers for the first installment of the "Sourcing Innovation" series. This segment delves into the intricate process of spinning out technologies from academia, providing invaluable insights from our distinguished advisors: Hani Goodarzi: Core Investigator Arc Institute, Associate Professor University of California, San Francisco David Schaffer: Director Bakar Labs/QB3, Distinguished professor University of California, Berkeley In the Sourcing Innovation series, we aim to broaden the discussion around academic entrepreneurship by exploring the spin-out process from two crucial perspectives: the PIs who lay the groundwork and the PhD trainees-turned-CEOs who bring these innovations to market.

🔈 CV Fireside Chat Series: Sourcing Innovation We want to extend a heartfelt thank you to our speakers for the first installment of the "Sourcing Innovation" series. This segment delves into the intricate process of spinning out technologies from academia, providing invaluable insights from our distinguished advisors: Hani Goodarzi: Core Investigator Arc Institute, Associate Professor University of California, San Francisco David Schaffer: Director Bakar Labs/QB3, Distinguished professor University of California, Berkeley In the Sourcing Innovation series, we aim to broaden the discussion around academic entrepreneurship by exploring the spin-out process from two crucial perspectives: the PIs who lay the groundwork and the PhD trainees-turned-CEOs who bring these innovations to market.